ライフサイエンスコーパス: CSII

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します

1 line, 2) after 4 weeks of CSII, and 3) after CSII plus either troglitazone or metformin.

2 bject, paired comparison of MDI and CSII and CSII with 12 months postislet transplantation in 10 type

3 within-subject, paired comparison of MDI and CSII and CSII with 12 months postislet transplantation i

4 s used randomized crossover design comparing CSII versus CLC during identical 22-h hospitalizations i

5 I group who completed the trial discontinued CSII.

6 on glycemic control and hypoglycemia, except CSII has a favorable effect on glycemic control in adult

7 ng automated data transfer CGM-->algorithm-->CSII.

8 ing effects than metformin (1,700 mg/day) in CSII-treated euglycemic patients.

9 ), continuous subcutaneous insulin infusion (CSII) and islet transplantation to reduce hypoglycemia a

10 of continuous subcutaneous insulin infusion (CSII) before randomization to CSII plus troglitazone (n

11 p (continuous subcutaneous insulin infusion [CSII]), known as artificial pancreas, can help optimize

12 y (continuous subcutaneous insulin infusion; CSII) in patients with type 1 diabetes using continuous

13 .9-10.0 mmol/L) is improved by initiation of CSII in adults with type 1 diabetes.

14 ic clamp 1) at baseline, 2) after 4 weeks of CSII, and 3) after CSII plus either troglitazone or metf

15 agents despite lower insulin levels than on CSII alone.

16 zation to CSII plus troglitazone (n = 10) or CSII plus metformin (n = 10); euglycemia was maintained

17 0.9; 3.3 mmol/mol [SD 9.8]) in the CGM plus CSII group and 0.1% (0.4; 1.1 mmol/mol [4.4]) in the CGM

18 36 (97%) of 37 participants in the CGM plus CSII group and 35 (92%) of 38 participants in the CGM pl

19 pants were randomly assigned to the CGM plus CSII group and 38 participants were randomly assigned to

20 s 6.7 days per week (SD 0.8) in the CGM plus CSII group and 6.9 days per week (0.3) in the CGM plus M

21 was 791 min per day (SD 157) in the CGM plus CSII group and 741 min per day (225) in the CGM plus MDI

22 Participants in the CGM plus CSII group had a greater reduction in CGM-measured mean

23 No participants in the CGM plus CSII group who completed the trial discontinued CSII.

24 rred in one participant each in the CGM plus CSII group.

25 I alone) and was then 45% higher than in the CSII plus metformin patients (P < 0.005).

26 After changing from MDI to CSII before transplantation, 10 subjects reduced median

27 hing from multiple daily injections (MDI) to CSII in adults with type 1 diabetes using CGM.

28 ulin infusion (CSII) before randomization to CSII plus troglitazone (n = 10) or CSII plus metformin (

29 erated sequence to continue MDI or switch to CSII, with continuation of CGM, for 28 weeks.

30 glycemia suitable for islet transplantation, CSII decreased hypoglycemia frequency and glycemic varia

31 reductions in all baseline parameters versus CSII, respectively, HbA1c (6.4% cf 8.2%), median HYPOsco

32 % with CSII plus troglitazone (P < 0.005 vs. CSII alone) and was then 45% higher than in the CSII plu

33 h CSII plus metformin, but improved 29% with CSII plus troglitazone (P < 0.005 vs. CSII alone) and wa

34 Good glycemic control was achieved with CSII alone and was maintained with CSII plus an oral age

35 ecreased 53% with troglitazone compared with CSII alone (48+/-4 vs. 102+/-13 U/day, P < 0.001), but o

36 eved with CSII alone and was maintained with CSII plus an oral agent (mean 24-h glucose: troglitazone

37 s mellitus, HbA1c levels decreased more with CSII than with MDI, but 1 study heavily influenced these

38 change significantly with CSII alone or with CSII plus metformin, but improved 29% with CSII plus tro

39 ensitivity did not change significantly with CSII alone or with CSII plus metformin, but improved 29%

40 time hypoglycemic on CGM were unchanged with CSII, SD glucose and CONGA4 reduced significantly (P < 0

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。